We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+2.96%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$460M
AUM Growth
+$84.2M
Cap. Flow
+$106M
Cap. Flow %
23.1%
Top 10 Hldgs %
34.98%
Holding
99
New
18
Increased
56
Reduced
8
Closed
16

Top Buys

Rank Stock Value
1
COO icon
Cooper Companies
COO
+$14.6M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$10.6M
3
BDX icon
Becton Dickinson
BDX
+$9.74M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$9.13M
5
ZBH icon
Zimmer Biomet
ZBH
+$8.16M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$14.7M
2
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$7.03M
3
DHR icon
Danaher
DHR
+$5.95M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$4.6M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$4.58M

Sector Composition

Rank Sector Weight
1 Healthcare 99.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
51
Veracyte
VCYT
$3.59B
$2.65M 0.58%
118,622
+896
+0.8% +$21.7K
XFOR icon
52
X4 Pharmaceuticals
XFOR
$425M
$2.43M 0.53%
93,238
+14,053
+18% +$412K
ISEE
53
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.36M 0.51%
97,082
+23,124
+31% +$506K
LEGN icon
54
Legend Biotech
LEGN
$3.99B
$2.3M 0.5%
47,608
-44,324
-48% -$2.17M
LQDA icon
55
Liquidia Corp
LQDA
$7.01B
$2.26M 0.49%
326,965
+57,773
+21% +$394K
AXGN icon
56
Axogen
AXGN
$2.67B
$2.11M 0.46%
223,783
+33,728
+18% +$308K
COGT icon
57
Cogent Biosciences
COGT
$6.76B
$1.96M 0.43%
181,896
+40,314
+28% +$516K
PRCT icon
58
Procept Biorobotics
PRCT
$1.22B
$1.91M 0.42%
67,252
-45,066
-40% -$1.59M
RCUS icon
59
Arcus Biosciences
RCUS
$3.69B
$1.88M 0.41%
102,987
+15,527
+18% +$297K
CGEM icon
60
Cullinan Oncology
CGEM
$1.26B
$1.74M 0.38%
169,886
+38,508
+29% +$425K
MRNS
61
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.73M 0.38%
+250,000
New +$1.57M
ESTA icon
62
Establishment Labs
ESTA
$2.25B
$1.69M 0.37%
+25,000
New +$1.71M
APLS
63
DELISTED
Apellis Pharmaceuticals
APLS
$1.65M 0.36%
+25,000
New +$1.44M
AKYA
64
DELISTED
Akoya BioSciences
AKYA
$1.65M 0.36%
201,385
+60,130
+43% +$628K
LXRX icon
65
Lexicon Pharmaceuticals
LXRX
$1.05B
$1.64M 0.36%
675,328
+254,126
+60% +$582K
NAMS icon
66
NewAmsterdam Pharma
NAMS
$3.33B
$1.52M 0.33%
+115,000
New +$1.45M
MIRM icon
67
Mirum Pharmaceuticals
MIRM
$6.04B
$1.49M 0.32%
62,118
+9,364
+18% +$213K
TELA icon
68
TELA Bio
TELA
$32.3M
$1.46M 0.32%
137,372
+20,704
+18% +$228K
GRTX
69
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$1.34M 0.29%
+525,000
New +$1.08M
ACRS icon
70
Aclaris Therapeutics
ACRS
$860M
$1.34M 0.29%
166,020
-81,139
-33% -$1.03M
SAGE
71
DELISTED
Sage Therapeutics
SAGE
$1.06M 0.23%
+25,321
New +$1.09M
SLN
72
Silence Therapeutics
SLN
$641M
$984K 0.21%
158,774
+23,932
+18% +$282K
TERN
73
DELISTED
Terns Pharmaceuticals
TERN
$888K 0.19%
+75,000
New +$717K
CDTX
74
DELISTED
Cidara Therapeutics
CDTX
$762K 0.17%
+30,000
New +$851K
INZY
75
DELISTED
Inozyme Pharma
INZY
$716K 0.16%
+125,000
New +$330K
1 2
3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Parkman Healthcare Partners held 99 positions worth $460M, up 22% from $376M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners deployed $106M of net new capital in Q1 2023, opening 18 new positions and adding to 56 existing holdings. Its largest new stake was Becton Dickinson: 39,788 shares worth $9.85M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Danaher, an estimated $5.95M trimmed.

  • Parkman Healthcare Partners's largest Q1 2023 buy was Becton Dickinson: 39,788 shares worth $9.85M.
  • Parkman Healthcare Partners added most to Cooper Companies in Q1 2023, an estimated $14.6M increase.
  • Parkman Healthcare Partners's biggest Q1 2023 reduction was Danaher, cutting an estimated $5.95M.
  • Parkman Healthcare Partners fully exited UnitedHealth in Q1 2023, selling an estimated $14.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $460M portfolio in Q1 2023.
  • Parkman Healthcare Partners opened 18 new positions and closed 16 in Q1 2023.
  • Parkman Healthcare Partners's portfolio value rose 22% quarter-over-quarter to $460M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2023, filed 12 May 2023.